Congenital and Pediatric Heart Disease

Our Work · Working GroupS

Congenital and Pediatric Heart Disease

A number of ongoing efforts to build knowledge, develop consensus, and ignite innovation in congenital, adult congenital, and pediatric heart disease.

Connecting expertise across congenital and pediatric heart disease to address critical gaps in care

Advancing heart health over a lifetime.

In order to address the wide-ranging landscape of issues impacting patients with congenital and pediatric heart diseases, H&VC has formed a number of clinical working groups. Through its Adult Congenital, Congenital Device Innovation, Pediatric, and Pediatric Engineering Working Groups, H&VC is developing focused initiatives that consider the entire life span of children with valve-related heart disease.

Leadership

Meet the group’s leadership

Aimee K. Armstrong
Aimee K. Armstrong, MD

Johns Hopkins Children’s Center / Johns Hopkins Medicine, Baltimore, MD

Pedro J. del Nido
Pedro J. del Nido, MD

Boston Children’s Hospital, Boston, MA

Stephanie Fuller
Stephanie Fuller, MD

Johns Hopkins Children’s Center, Baltimore, MD

Anne Marie Valente
Anne Marie Valente, MD

Brigham and Women’s Hospital, Boston, MA

Carole A. Warnes
Carole A. Warnes, MD

Mayo Clinic, Rochester, MN

Ajit P. Yoganathan
Ajit P. Yoganathan, PhD

Georgia Tech & Emory University, Atlanta, GA

Learn more from this working group

Publication · 2024

Congenital and Pediatric Heart Disease

This summary document reviews the current state of valve therapy for pediatric and congenital heart disease patients and the needs being addressed for continued valve development.

Apple Podcasts

↗

Spotify

↗

Watch the video

↗

Podcast · 22 min

Video · 22 min

Congenital and Pediatric Heart Disease

Bioprosthetic Valve Durability: A Multi-Disciplinary Approach

Martin Leon, Philippe Pibarot, and Ajit Yoganathan discuss the evolving understanding of bioprosthetic valve failure, the challenges of tissue deterioration, and the need for improved testing and collaboration to enhance valve longevity, especially for younger patients.

Read the publication

↗

↗

Watch the video

↗

ACHD Heart Failure Innovation Summit: Define, Prevent, Treat, Support Workshop

May 21 & 22, 2026
Course Directors: Aimee Armstrong, Stephanie Fuller, Anne Marie Valente, Carole Warnes

Presentation: Day 2, 9:32 – 9:40
FDA: What Will it Take to Design a Device Regulatory Trial for this Population
Gavin D’Souza

Co-sponsored by

Watch the video

Explore other working groups

Find out what other H&VC working groups have developed.

Working group

A global group of leading experts working to advance knowledge and share best practices in the prevention and treatment of rheumatic heart disease.

Explore the group

Rheumatic Heart Disease

Working group

This working group is addressing the evolving landscape of clinical trial conduct in the modern era through proof-of-concept projects, publications, and more.

Explore the group

Clinical Trial Modernization

Subscribe to our newsletter

Get news and updates from the Heart & Valve Collaboratory.

By subscribing, you agree to our Privacy Policy.